VNX001 for Interstitial Cystitis / Bladder Pain Syndrome
This study is testing VNX001, given directly into the bladder (intravesical administration), for people with Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS). The goal is to see how often VNX001 is used "as needed" (PRN) to treat moderate to severe bladder pain over 14 days. Researchers will also look at how safe VNX001 is and how well people tolerate it. To join, you must have already completed Study VNX001-111 and meet other requirements. The study plans to enroll about 50 participants and is currently open.
- Study design
- This is an open-label study, meaning both you and the study team will know you are receiving VNX001. It aims to enroll about 50 participants.
- What's involved
- You will have up to seven clinic visits or one clinic visit and five phone visits over 14 days. During clinic visits, you may receive VNX001 through a catheter into your bladder.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary measurement for this study is taken at 14 days.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)
At a glance
Conditions
Where it's being run
5 sites across 4 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Exclusion
What this trial measures
- Frequency of PRN intravesical administrations of VNX00114 Days